Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Sign Up
Cited by 20

The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.

TP53 in AML and MDS: The new (old) kid on the block

Marks, Jennifer A., Wang, Xin, Fenu, Elena M., Bagg, Adam, Lai, Catherine·2023·Blood Reviews
DOI 10.1016/j.blre.2023.101055
Open this paper in CoChat — free account

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.blre.2023.101055

Cites

31 of 31 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 31 references

Research works printed but not linked: 149

  1. Papaemmanuil, 2016, Genomic classification and prognosis in acute myeloid leukemia, N Engl J Med, 374, 2209, 10.1056/NEJMoa1516192 · DOI · Paper page
  2. Sperling, 2017, The genetics of myelodysplastic syndrome: from clonal haematopoiesis to secondary leukaemia, Nat Rev Cancer, 17, 5, 10.1038/nrc.2016.112 · DOI · Paper page
  3. Sebaa, 2012, Incidence of 17p deletions and TP53 mutation in myelodysplastic syndrome and acute myeloid leukemia with 5q deletion, Genes Chromosomes Cancer, 51, 1086, 10.1002/gcc.21993 · DOI
  4. Ogawa, 2019, Genetics of MDS, Blood, 133, 1049, 10.1182/blood-2018-10-844621 · DOI · Paper page
  5. DiNardo, 2016, Mutations in AML: prognostic and therapeutic implications, Hematology Am Soc Hematol Educ Program, 2016, 348, 10.1182/asheducation-2016.1.348 · DOI · Paper page
  6. Bejar, 2014, Clinical and genetic predictors of prognosis in myelodysplastic syndromes, Haematologica, 99, 956, 10.3324/haematol.2013.085217 · DOI
  7. Daver, 2022, TP53-mutated myelodysplastic syndrome and acute myeloid leukemia: biology, current therapy, and future directions, Cancer Discov, OF1
  8. Vogelstein, 2000, Surfing the p53 network, Nature, 408, 307, 10.1038/35042675 · DOI · Paper page
  9. Zhang, 2017, The role of p53 in myelodysplastic syndromes and acute myeloid leukemia: molecular aspects and clinical implications, Leuk Lymphoma, 58, 1777, 10.1080/10428194.2016.1266625 · DOI
  10. Christiansen, 2001, Mutations with loss of heterozygosity of p53 are common in therapy-related myelodysplasia and acute myeloid leukemia after exposure to alkylating agents and significantly associated with deletion or loss of 5q, a complex karyotype, and a poor prognosis, J Clin Oncol, 19, 1405, 10.1200/JCO.2001.19.5.1405 · DOI · Paper page
  11. Ben-Yehuda, 1996, Microsatellite instability and p53 mutations in therapy-related leukemia suggest mutator phenotype, Blood, 88, 4296, 10.1182/blood.V88.11.4296.bloodjournal88114296 · doi:10.1182/blood.v88.11.4296.bloodjournal88114296 · Paper page
  12. Lee, 2019, Molecular pathogenesis of myelodysplastic syndromes with deletion 5q, Eur J Haematol, 102, 203, 10.1111/ejh.13207 · DOI
  13. Cumbo, 2020, TP53 in myelodysplastic syndromes: recent biological and clinical findings, Int J Mol Sci, 21, 10.3390/ijms21103432 · DOI
  14. Joerger, 2010, The tumor suppressor p53: from structures to drug discovery, Cold Spring Harb Perspect Biol, 2, 10.1101/cshperspect.a000919 · DOI · Paper page
  15. Stengel, 2017, The impact of TP53 mutations and TP53 deletions on survival varies between AML, ALL, MDS and CLL: an analysis of 3307 cases, Leukemia, 31, 705, 10.1038/leu.2016.263 · DOI · Paper page
  16. Assi, 2018, P53 protein overexpression in de novo acute myeloid leukemia patients with normal diploid karyotype correlates with FLT3 internal tandem duplication and worse relapse-free survival, Am J Hematol, 93, 1376, 10.1002/ajh.25255 · DOI
  17. Grob, 2022, Molecular characterization of mutant TP53 acute myeloid leukemia and high-risk myelodysplastic syndrome, Blood, 139, 2347, 10.1182/blood.2021014472 · DOI · Paper page
  18. Sallman, 2016, Impact of TP53 mutation variant allele frequency on phenotype and outcomes in myelodysplastic syndromes, Leukemia, 30, 666, 10.1038/leu.2015.304 · DOI · Paper page
  19. Jiang, 2021, TP53 in myelodysplastic syndromes, Cancers (Basel), 13, 10.3390/cancers13215392 · DOI
  20. Kadia, 2016, TP53 mutations in newly diagnosed acute myeloid leukemia: clinicomolecular characteristics, response to therapy, and outcomes, Cancer, 122, 3484, 10.1002/cncr.30203 · DOI · Paper page
  21. Khoury, 2022, The 5th edition of the World Health Organization classification of haematolymphoid tumours: myeloid and histiocytic/dendritic neoplasms, Leukemia, 36, 1703, 10.1038/s41375-022-01613-1 · DOI · Paper page
  22. Levine, 2020, p53: 800 million years of evolution and 40 years of discovery, Nat Rev Cancer, 20, 471, 10.1038/s41568-020-0262-1 · DOI · Paper page
  23. Klimovich, 2022, p53 partial loss-of-function mutations sensitize to chemotherapy, Oncogene, 41, 1011, 10.1038/s41388-021-02141-5 · DOI · Paper page
  24. Donehower, 2019, Integrated analysis of TP53 gene and pathway alterations in the cancer genome atlas, Cell Rep, 28, 3010, 10.1016/j.celrep.2019.08.061 · DOI · Paper page
  25. Prochazka, 2019, Clinical implications of subclonal TP53 mutations in acute myeloid leukemia, Haematologica, 104, 516, 10.3324/haematol.2018.205013 · DOI
  26. Surget, 2014, Uncovering the role of p53 splice variants in human malignancy: a clinical perspective, Onco Targets Ther, 7, 57
  27. El Marabti, 2018, The cancer spliceome: reprograming of alternative splicing in cancer, Front Mol Biosci, 5, 80, 10.3389/fmolb.2018.00080 · DOI · Paper page
  28. Rivlin, 2011, Mutations in the p53 tumor suppressor gene: important milestones at the various steps of tumorigenesis, Genes Cancer, 2, 466, 10.1177/1947601911408889 · DOI · Paper page
  29. Molica, 2020, TP53 mutations in acute myeloid leukemia: still a daunting challenge?, Front Oncol, 10
  30. Dohner, 2022, Diagnosis and management of AML in adults: 2022 ELN recommendations from an international expert panel, Blood, 140, 1345, 10.1182/blood.2022016867 · DOI · Paper page
  31. Arber, 2016, The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia, Blood, 127, 2391, 10.1182/blood-2016-03-643544 · DOI · Paper page
  32. Nguyen-Khac, 2022, The complex karyotype in hematological malignancies: a comprehensive overview by the Francophone Group of Hematological Cytogenetics (GFCH), Leukemia, 36, 1451, 10.1038/s41375-022-01561-w · DOI
  33. Schoch, 2004, Karyotype is an independent prognostic parameter in therapy-related acute myeloid leukemia (t-AML): an analysis of 93 patients with t-AML in comparison to 1091 patients with de novo AML, Leukemia, 18, 120, 10.1038/sj.leu.2403187 · DOI · Paper page
  34. Kuendgen, 2021, Therapy-related myelodysplastic syndromes deserve specific diagnostic sub-classification and risk-stratification-an approach to classification of patients with t-MDS, Leukemia, 35, 835, 10.1038/s41375-020-0917-7 · DOI
  35. Greenberg, 2012, Revised international prognostic scoring system for myelodysplastic syndromes, Blood J Am Soc Hematol., 120, 2454
  36. Weinberg, 2022, TP53 mutation defines a unique subgroup within complex karyotype de novo and therapy-related MDS/AML, Blood Adv, 6, 2847, 10.1182/bloodadvances.2021006239 · DOI · Paper page
  37. Rucker, 2012, TP53 alterations in acute myeloid leukemia with complex karyotype correlate with specific copy number alterations, monosomal karyotype, and dismal outcome, Blood, 119, 2114, 10.1182/blood-2011-08-375758 · DOI · Paper page
  38. Ebert, 2011, Molecular dissection of the 5q deletion in myelodysplastic syndrome, Semin Oncol, 38, 621, 10.1053/j.seminoncol.2011.04.010 · DOI
  39. Bersanelli, 2021, Classification and personalized prognostic assessment on the basis of clinical and genomic features in myelodysplastic syndromes, J Clin Oncol, 39, 1223, 10.1200/JCO.20.01659 · DOI · Paper page
  40. Zemanova, 2018, Chromothripsis in high-risk myelodysplastic syndromes: incidence, genetic features, clinical implications, and impact on survival of patients treated with azacytidine (data from Czech MDS Group), Blood, 132, 1815, 10.1182/blood-2018-99-114151 · doi:10.1182/blood-2018-99-114151
  41. Cluzeau, 2021, Personalized medicine for TP53 mutated myelodysplastic syndromes and acute myeloid leukemia, Int J Mol Sci, 22, 10.3390/ijms221810105 · DOI
  42. Quesada, 2019, DDX41 mutations in myeloid neoplasms are associated with male gender, TP53 mutations and high-risk disease, Am J Hematol, 94, 757, 10.1002/ajh.25486 · DOI
  43. Garber, 1991, Follow-up study of twenty-four families with Li-Fraumeni syndrome, Cancer Res, 51, 6094
  44. Kuendgen, 2006, Myelodysplastic syndromes in patients younger than age 50, J Clin Oncol, 24, 5358, 10.1200/JCO.2006.07.5598 · DOI
  45. Jaiswal, 2014, Age-related clonal hematopoiesis associated with adverse outcomes, N Engl J Med, 371, 2488, 10.1056/NEJMoa1408617 · DOI · Paper page
  46. Babushok, 2016, Genetic predisposition to myelodysplastic syndrome and acute myeloid leukemia in children and young adults, Leuk Lymphoma, 57, 520, 10.3109/10428194.2015.1115041 · DOI
  47. Klco, 2021, Advances in germline predisposition to acute leukaemias and myeloid neoplasms, Nat Rev Cancer, 21, 122, 10.1038/s41568-020-00315-z · DOI
  48. Singhal, 2017, Presence of rare germline variants in Fanconi anaemia pathway genes confers a poor prognosis comparable to TP53 mutations in therapy-related myeloid neoplasms, Blood, 130, 4231
  49. Swaminathan, 2019, Hematologic malignancies and Li-Fraumeni syndrome, Cold Spring Harb Mol Case Stud, 5, 10.1101/mcs.a003210 · DOI
  50. Leone, 2003, Inhibitors of DNA methylation in the treatment of hematological malignancies and MDS, Clin Immunol, 109, 89, 10.1016/S1521-6616(03)00207-9 · DOI
  51. Deng, 2020, The prognostic impact of variant allele frequency (VAF) in TP53 mutant patients with MDS: a systematic review and meta-analysis, Eur J Haematol, 105, 524, 10.1111/ejh.13483 · DOI
  52. Goel, 2016, High prevalence and allele burden-independent prognostic importance of p53 mutations in an inner-city MDS/AML cohort, Leukemia, 30, 1793, 10.1038/leu.2016.74 · DOI
  53. Döhner, 2017, Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel, Blood, 129, 424, 10.1182/blood-2016-08-733196 · DOI · Paper page
  54. Zeidan, 2023, Prognostic implications of mono-hit and multi-hit TP53 alterations in patients with acute myeloid leukemia and higher risk myelodysplastic syndromes treated with azacitidine-based therapy, Leukemia, 37, 240, 10.1038/s41375-022-01766-z · DOI
  55. Ebert, 2008, Identification of RPS14 as a 5q- syndrome gene by RNA interference screen, Nature, 451, 335, 10.1038/nature06494 · DOI · Paper page
  56. Shahjahani, 2019, Complex karyotype in myelodysplastic syndromes: diagnostic procedure and prognostic susceptibility, Oncol Rev, 13, 389, 10.4081/oncol.2019.389 · DOI
  57. Akkari, 2022, Guiding the global evolution of cytogenetic testing for hematologic malignancies, Blood, 139, 2273, 10.1182/blood.2021014309 · DOI
  58. Duncavage, 2022, Genomic profiling for clinical decision making in myeloid neoplasms and acute leukemia, Blood, 140, 2228, 10.1182/blood.2022015853 · DOI · Paper page
  59. Peterson, 2018, The utilization of chromosomal microarray technologies for hematologic neoplasms: an ACLPS critical review, Am J Clin Pathol, 150, 375, 10.1093/ajcp/aqy076 · DOI
  60. Chauffaille, 2020, Detection of somatic TP53 mutations and 17p deletions in patients with chronic lymphocytic leukemia: a review of the current methods, Hematol Transfus Cell Ther, 42, 261, 10.1016/j.htct.2020.05.005 · DOI
  61. Greenberg, 2022, NCCN guidelines(R) insights: myelodysplastic syndromes, version 3.2022, J Natl Compr Canc Netw, 20, 106, 10.6004/jnccn.2022.0009 · DOI
  62. Heuser, 2021, 2021 update on MRD in acute myeloid leukemia: a consensus document from the European LeukemiaNet MRD Working Party, Blood, 138, 2753, 10.1182/blood.2021013626 · DOI · Paper page
  63. Bacher, 2018, Challenges in the introduction of next-generation sequencing (NGS) for diagnostics of myeloid malignancies into clinical routine use, Blood Cancer J, 8, 113, 10.1038/s41408-018-0148-6 · DOI
  64. Soussi, 2022, Benign SNPs in the coding region of TP53: finding the needles in a haystack of pathogenic variants, Cancer Res, 82, 3420, 10.1158/0008-5472.CAN-22-0172 · DOI
  65. Malcikova, 2018, ERIC recommendations for TP53 mutation analysis in chronic lymphocytic leukemia-update on methodological approaches and results interpretation, Leukemia, 32, 1070, 10.1038/s41375-017-0007-7 · DOI · Paper page
  66. Miura, 2021, A simple method to estimate the in-house limit of detection for genetic mutations with low allele frequencies in whole-exome sequencing analysis by next-generation sequencing, BMC Genom Data, 22, 8, 10.1186/s12863-020-00956-x · DOI
  67. Bally, 2014, Detection of TP53 mutations in myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML). A comparison between a functional method (FASAY) and next generation sequencing (NGS), Blood, 124, 3266, 10.1182/blood.V124.21.3266.3266 · doi:10.1182/blood.v124.21.3266.3266
  68. Tonisson, 2002, Evaluating the arrayed primer extension resequencing assay of TP53 tumor suppressor gene, Proc Natl Acad Sci U S A, 99, 5503, 10.1073/pnas.082100599 · DOI
  69. Kantorova, 2015, TP53 mutation analysis in chronic lymphocytic leukemia: comparison of different detection methods, Tumour Biol, 36, 3371, 10.1007/s13277-014-2971-0 · DOI
  70. Malcikova, 2015, Detailed analysis of therapy-driven clonal evolution of TP53 mutations in chronic lymphocytic leukemia, Leukemia, 29, 877, 10.1038/leu.2014.297 · DOI
  71. Kringen, 2005, Evaluation of arrayed primer extension for TP53 mutation detection in breast and ovarian carcinomas, Biotechniques, 39, 755, 10.2144/000112000 · DOI
  72. Seifert, 2009, The prognostic impact of 17p (p53) deletion in 2272 adults with acute myeloid leukemia, Leukemia, 23, 656, 10.1038/leu.2008.375 · DOI · Paper page
  73. Merlat, 1999, Therapy-related myelodysplastic syndrome and acute myeloid leukemia with 17p deletion. A report on 25 cases, Leukemia, 13, 250, 10.1038/sj.leu.2401298 · DOI
  74. Sanchez-Castro, 2013, Characterization and prognostic implication of 17 chromosome abnormalities in myelodysplastic syndrome, Leuk Res, 37, 769, 10.1016/j.leukres.2013.04.010 · doi:10.1016/j.leukres.2013.04.010
  75. Sanchez-Castro, 2015, Fluorescence in situ hybridization of TP53 for the detection of chromosome 17 abnormalities in myelodysplastic syndromes, Leuk Lymphoma, 56, 3183, 10.3109/10428194.2015.1028053 · DOI
  76. Malcovati, 2013, Diagnosis and treatment of primary myelodysplastic syndromes in adults: recommendations from the European LeukemiaNet, Blood, 122, 2943, 10.1182/blood-2013-03-492884 · DOI · Paper page
  77. Ribeiro, 2021, Genomic variations in patients with myelodysplastic syndrome and karyotypes without numerical or structural changes, Sci Rep, 11, 2783, 10.1038/s41598-021-81467-2 · DOI
  78. Berry, 2019, Clinical use of SNP-microarrays for the detection of genome-wide changes in haematological malignancies, Crit Rev Oncol Hematol, 142, 58, 10.1016/j.critrevonc.2019.07.016 · DOI
  79. Arenillas, 2013, Single nucleotide polymorphism array karyotyping: a diagnostic and prognostic tool in myelodysplastic syndromes with unsuccessful conventional cytogenetic testing, Genes Chromosomes Cancer, 52, 1167, 10.1002/gcc.22112 · DOI
  80. Yang, 2022, High-resolution structural variant profiling of myelodysplastic syndromes by optical genome mapping uncovers cryptic aberrations of prognostic and therapeutic significance, Leukemia, 36, 2306, 10.1038/s41375-022-01652-8 · DOI
  81. Raffone, 2020, Diagnostic accuracy of p53 immunohistochemistry as surrogate of TP53 sequencing in endometrial cancer, Pathol Res Pract, 216, 10.1016/j.prp.2020.153025 · DOI
  82. Kortekaas, 2020, Performance of the pattern-based interpretation of p53 immunohistochemistry as a surrogate for TP53 mutations in vulvar squamous cell carcinoma, Histopathology, 77, 92, 10.1111/his.14109 · DOI
  83. Yu, 2021, TP53 co-mutational features and NGS-calibrated immunohistochemistry threshold in gastric cancer, Onco Targets Ther, 14, 4967, 10.2147/OTT.S321949 · DOI
  84. McGraw, 2016, Immunohistochemical pattern of p53 is a measure of TP53 mutation burden and adverse clinical outcome in myelodysplastic syndromes and secondary acute myeloid leukemia, Haematologica, 101, e320, 10.3324/haematol.2016.143214 · DOI
  85. Ruzinova, 2019, TP53 immunohistochemistry correlates with TP53 mutation status and clearance in decitabine-treated patients with myeloid malignancies, Haematologica, 104, e345, 10.3324/haematol.2018.205302 · DOI
  86. Fitzpatrick, 2022, Correlation of p53 immunohistochemistry with TP53 mutational status and overall survival in newly diagnosed acute myeloid leukaemia, Histopathology, 81, 496, 10.1111/his.14726 · DOI
  87. Fernandez-Pol, 2017, Immunohistochemistry for p53 is a useful tool to identify cases of acute myeloid leukemia with myelodysplasia-related changes that are TP53 mutated, have complex karyotype, and have poor prognosis, Mod Pathol, 30, 382, 10.1038/modpathol.2016.206 · DOI
  88. Chui, 2022, Somatic intronic TP53 c.375+5G mutations are a recurrent but under-recognized mode of TP53 inactivation, J Pathol Clin Res, 8, 14, 10.1002/cjp2.242 · doi:10.1002/cjp2.242
  89. Fang, 2022, Pure erythroid leukemia is characterized by biallelic TP53 inactivation and abnormal p53 expression patterns in de novo and secondary cases, Haematologica, 107, 2232, 10.3324/haematol.2021.280487 · DOI
  90. Sangoi, 2022, p53 null phenotype is a "positive result" in urothelial carcinoma in situ, Mod Pathol, 35, 1287, 10.1038/s41379-022-01062-2 · doi:10.1038/s41379-022-01062-2
  91. Orachum, 2022, Clinical outcomes of immunohistochemistry of the p53 staining pattern in high-grade serous ovarian carcinoma, Obstet Gynecol Sci, 65, 459, 10.5468/ogs.22102 · DOI
  92. Salomao, 2022, Reduced murine double minute 2 and 4 protein, but not messenger RNA, expression is associated with more severe disease in myelodysplastic syndromes and acute myeloblastic leukaemia, Br. J. Haematol.
  93. Loschi, 2022, How I treat TP53-mutated acute myeloid leukemia and myelodysplastic syndromes, Cancers, 14, 4519, 10.3390/cancers14184519 · DOI
  94. Granowicz, 2022, Targeting TP53-mutated acute myeloid leukemia: research and clinical developments, Onco Targets Ther, 15, 423, 10.2147/OTT.S265637 · DOI
  95. Kuykendall, 2018, Acute myeloid leukemia: the good, the bad, and the ugly, Am Soc Clin Oncol Educ Book, 38, 555, 10.1200/EDBK_199519 · DOI
  96. Bowen, 2009, TP53 gene mutation is frequent in patients with acute myeloid leukemia and complex karyotype, and is associated with very poor prognosis, Leukemia, 23, 203, 10.1038/leu.2008.173 · DOI · Paper page
  97. Goldberg, 2018, TP53 mutations predict poorer responses to CPX-351 in acute myeloid leukemia, Blood, 132, 1433, 10.1182/blood-2018-99-117772 · DOI
  98. Hills, 2014, Addition of gemtuzumab ozogamicin to induction chemotherapy in adult patients with acute myeloid leukaemia: a meta-analysis of individual patient data from randomised controlled trials, Lancet Oncol, 15, 986, 10.1016/S1470-2045(14)70281-5 · DOI · Paper page
  99. Muller-Thomas, 2014, Response to azacitidine is independent of p53 expression in higher-risk myelodysplastic syndromes and secondary acute myeloid leukemia, Haematologica, 99, e179, 10.3324/haematol.2014.104760 · DOI
  100. Dohner, 2018, Cytogenetics and gene mutations influence survival in older patients with acute myeloid leukemia treated with azacitidine or conventional care, Leukemia, 32, 2546, 10.1038/s41375-018-0257-z · DOI
  101. Middeke, 2021, Decitabine treatment in 311 patients with acute myeloid leukemia: outcome and impact of TP53 mutations - a registry based analysis, Leuk Lymphoma, 62, 1432, 10.1080/10428194.2020.1864354 · DOI
  102. Boddu, 2018, Outcomes with lower intensity therapy in TP53-mutated acute myeloid leukemia, Leuk Lymphoma, 59, 2238, 10.1080/10428194.2017.1422864 · DOI
  103. DiNardo, 2020, Azacitidine and venetoclax in previously untreated acute myeloid leukemia, N Engl J Med, 383, 617, 10.1056/NEJMoa2012971 · DOI · Paper page
  104. DiNardo, 2019, Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia, Blood, 133, 7, 10.1182/blood-2018-08-868752 · DOI · Paper page
  105. Aldoss, 2019, Venetoclax and hypomethylating agents in TP53-mutated acute myeloid leukaemia, Br J Haematol, 187, e45, 10.1111/bjh.16166 · DOI
  106. DiNardo, 2020, 10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-Centre, phase 2 trial, Lancet Haematol, 7, e724, 10.1016/S2352-3026(20)30210-6 · DOI · Paper page
  107. Cluzeau, 2021, Eprenetapopt plus azacitidine in TP53-mutated myelodysplastic syndromes and acute myeloid leukemia: a phase II study by the Groupe Francophone des Myelodysplasies (GFM), J Clin Oncol, 39, 1575, 10.1200/JCO.20.02342 · DOI · Paper page
  108. Daver, 2022, Tolerability and efficacy of the first-in-class anti-CD47 antibody magrolimab combined with azacitidine in frontline TP53m AML patients: phase 1b results, J Clin Oncol, 40, 7020, 10.1200/JCO.2022.40.16_suppl.7020 · DOI
  109. Daver, 2021, Phase I/II study of azacitidine (AZA) with venetoclax (VEN) and magrolimab (Magro) in patients (pts) with newly diagnosed older/unfit or high-risk acute myeloid leukemia (AML) and relapsed/refractory (R/R) AML, Blood, 138, 371, 10.1182/blood-2021-153638 · DOI
  110. Brunner, 2021, Efficacy and safety of sabatolimab (MBG453) in combination with hypomethylating agents (HMAs) in patients (Pts) with very high/high-risk myelodysplastic syndrome (vHR/HR-MDS) and acute myeloid leukemia (AML): final analysis from a phase Ib study, Blood, 138, 244, 10.1182/blood-2021-146039 · DOI
  111. Vadakekolathu, 2020, TP53 abnormalities correlate with immune infiltration and associate with response to flotetuzumab immunotherapy in AML, Blood Adv, 4, 5011, 10.1182/bloodadvances.2020002512 · DOI
  112. Uy, 2021, Flotetuzumab as salvage immunotherapy for refractory acute myeloid leukemia, Blood, 137, 751, 10.1182/blood.2020007732 · DOI · Paper page
  113. Takahashi, 2016, Clinical implications of TP53 mutations in myelodysplastic syndromes treated with hypomethylating agents, Oncotarget, 7, 14172, 10.18632/oncotarget.7290 · DOI
  114. Chang, 2017, TP53 mutations predict decitabine-induced complete responses in patients with myelodysplastic syndromes, Br J Haematol, 176, 600, 10.1111/bjh.14455 · DOI
  115. Welch, 2016, TP53 and decitabine in acute myeloid leukemia and myelodysplastic syndromes, N Engl J Med, 375, 2023, 10.1056/NEJMoa1605949 · DOI · Paper page
  116. Bazinet, 2022, Azacitidine plus venetoclax in patients with high-risk myelodysplastic syndromes or chronic myelomonocytic leukaemia: phase 1 results of a single-centre, dose-escalation, dose-expansion, phase 1–2 study, Lancet Haematol, 9, e756, 10.1016/S2352-3026(22)00216-2 · DOI
  117. Zeidan, 2023, A phase 1b study of venetoclax and azacitidine combination in patients with relapsed or refractory myelodysplastic syndromes, Am J Hematol, 98, 272, 10.1002/ajh.26771 · DOI
  118. Sallman, 2022, Magrolimab in combination with azacitidine for untreated higher-risk myelodysplastic syndromes (HR-MDS): 5F9005 phase 1b study results, J Clin Oncol, 40, 7017, 10.1200/JCO.2022.40.16_suppl.7017 · DOI
  119. Mishra, 2021, Phase II trial of eprenetapopt (APR-246) in combination with azacitidine (AZA) as maintenance therapy for TP53 mutated AML or MDS following allogeneic stem cell transplantation (SCT), Blood, 138, 409, 10.1182/blood-2021-147962 · DOI
  120. Hou, 2015, TP53 mutations in de novo acute myeloid leukemia patients: longitudinal follow-ups show the mutation is stable during disease evolution, Blood Cancer J, 5, 10.1038/bcj.2015.59 · DOI · Paper page
  121. Lancet, 2018, CPX-351 (cytarabine and daunorubicin) liposome for injection versus conventional cytarabine plus daunorubicin in older patients with newly diagnosed secondary acute myeloid leukemia, J Clin Oncol, 36, 2684, 10.1200/JCO.2017.77.6112 · DOI · Paper page
  122. Wei, 2020, Oral azacitidine maintenance therapy for acute myeloid leukemia in first remission, N Engl J Med, 383, 2526, 10.1056/NEJMoa2004444 · DOI · Paper page
  123. Jin, 2020, 5-azacitidine induces NOXA to prime AML cells for venetoclax-mediated apoptosis, Clin Cancer Res, 26, 3371, 10.1158/1078-0432.CCR-19-1900 · DOI · Paper page
  124. Bogenberger, 2015, Ex vivo activity of BCL-2 family inhibitors ABT-199 and ABT-737 combined with 5-azacytidine in myeloid malignancies, Leuk Lymphoma, 56, 226, 10.3109/10428194.2014.910657 · DOI
  125. Garcia, 2020, Safety, efficacy, and patient-reported outcomes of venetoclax in combination with azacitidine for the treatment of patients with higher-risk myelodysplastic syndrome: a phase 1b study, Blood, 136, 55, 10.1182/blood-2020-139492 · DOI
  126. Poire, 2017, Allogeneic stem cell transplantation in adult patients with acute myeloid leukaemia and 17p abnormalities in first complete remission: a study from the Acute Leukemia Working Party (ALWP) of the European Society for Blood and Marrow Transplantation (EBMT), J Hematol Oncol, 10, 20, 10.1186/s13045-017-0393-3 · DOI
  127. Gilleece, 2018, Am J Hematol, 93, 1142, 10.1002/ajh.25211 · DOI
  128. Walter, 2013, Significance of minimal residual disease before myeloablative allogeneic hematopoietic cell transplantation for AML in first and second complete remission, Blood, 122, 1813, 10.1182/blood-2013-06-506725 · DOI · Paper page
  129. Gilleece, 2021, Measurable residual disease status and outcome of transplant in acute myeloid leukemia in second complete remission: a study by the acute leukemia working party of the EBMT, Blood Cancer J, 11, 88, 10.1038/s41408-021-00479-3 · DOI
  130. Chan, 2019, Impact of TP53 gene mutation clearance and conditioning intensity on outcome in MDS or AML patients prior to allogeneic stem cell transplantation, Blood, 134, 149, 10.1182/blood-2019-131530 · doi:10.1182/blood-2019-131530
  131. Scott, 2020, Allogeneic stem cell transplantation for high-risk acute leukemia and maintenance therapy: no time to waste, Blood Adv, 4, 3200, 10.1182/bloodadvances.2019000388 · doi:10.1182/bloodadvances.2019000388
  132. Burchert, 2020, Sorafenib maintenance after allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia with FLT3-internal tandem duplication mutation (SORMAIN), J Clin Oncol, 38, 2993, 10.1200/JCO.19.03345 · DOI · Paper page
  133. Sahasrabudhe, 2022, Novel investigational approaches for high-risk genetic subsets of AML: TP53, KMT2A, FLT3, Hematology Am Soc Hematol Educ Program, 2022, 15, 10.1182/hematology.2022000325 · DOI
  134. Bykov, 2016, Targeting of mutant p53 and the cellular redox balance by APR-246 as a strategy for efficient cancer therapy, Front Oncol, 6, 21, 10.3389/fonc.2016.00021 · DOI · Paper page
  135. Takimoto, 2019, The macrophage ‘Do not eat me’ signal, CD47, is a clinically validated cancer immunotherapy target, Ann Oncol, 30, 486, 10.1093/annonc/mdz006 · DOI
  136. Swoboda, 2020, The promise of macrophage directed checkpoint inhibitors in myeloid malignancies, Best Pract Res Clin Haematol, 33, 10.1016/j.beha.2020.101221 · DOI
  137. Daver, 2022, Phase I/II study of azacitidine (AZA) with venetoclax (VEN) and magrolimab (Magro) in patients (pts) with newly diagnosed (ND) older/unfit or high-risk acute myeloid leukemia (AML) and relapsed/refractory (R/R) AML, Blood, 140, 141, 10.1182/blood-2022-170188 · DOI
  138. Chao, 2019, Therapeutic targeting of the macrophage immune checkpoint CD47 in myeloid malignancies, Front Oncol, 9, 1380, 10.3389/fonc.2019.01380 · DOI · Paper page
  139. Brierley, 2019, The effects of monoclonal anti-CD47 on RBCs, compatibility testing, and transfusion requirements in refractory acute myeloid leukemia, Transfusion, 59, 2248, 10.1111/trf.15397 · DOI
  140. Sallman, 2019, The first-in-class anti-CD47 antibody magrolimab (5F9) in combination with azacitidine is effective in MDS and AML patients: ongoing phase 1b results, Blood, 134, 569, 10.1182/blood-2019-126271 · DOI · Paper page
  141. Zeidan, 2021, TIM-3 pathway dysregulation and targeting in cancer, Expert Rev Anticancer Ther, 21, 523, 10.1080/14737140.2021.1865814 · DOI
  142. Zeidan, 2021, Sabatolimab (MBG453) combination treatment regimens for patients (pts) with higher-risk myelodysplastic syndromes (HR-MDS): the MDS studies in the stimulus immuno-myeloid clinical trial program, Blood, 138, 4669, 10.1182/blood-2021-145626 · doi:10.1182/blood-2021-145626
  143. Al-Hussaini, 2016, Targeting CD123 in acute myeloid leukemia using a T-cell-directed dual-affinity retargeting platform, Blood, 127, 122, 10.1182/blood-2014-05-575704 · DOI · Paper page
  144. Chichili, 2015, A CD3xCD123 bispecific DART for redirecting host T cells to myelogenous leukemia: preclinical activity and safety in nonhuman primates, Sci Transl Med, 7, 289, 10.1126/scitranslmed.aaa5693 · DOI · Paper page
  145. Erba, 2019, Phase 1b study of the MDM2 inhibitor AMG 232 with or without trametinib in relapsed/refractory acute myeloid leukemia, Blood Adv, 3, 1939, 10.1182/bloodadvances.2019030916 · DOI · Paper page
  146. Mirgayazova, 2020, Therapeutic editing of the TP53 gene: is CRISPR/Cas9 an option?, Genes (Basel), 11, 10.3390/genes11060704 · DOI
  147. Maute, 2022, CD47-SIRPalpha-targeted therapeutics: status and prospects, Immunooncol Technol, 13
  148. Abaigar, 2016, Chromothripsis is a recurrent genomic abnormality in high-risk myelodysplastic syndromes, PLoS One, 11, 10.1371/journal.pone.0164370 · DOI
  149. Forment, 2012, Chromothripsis and cancer: causes and consequences of chromosome shattering, Nat Rev Cancer, 12, 663, 10.1038/nrc3352 · DOI · Paper page

Cited by

See all 20

Metadata

Authors
Marks, J. A., Wang, X., Fenu, E. M., Bagg, A., & Lai, C.
Venue
Blood Reviews
Publisher
Elsevier BV
Published
2023-07
Volume
60
Pages
101055
ISSN
0268-960X
DOI
10.1016/j.blre.2023.101055
Cited by
20
References
31
Language
en
Licence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: TP53 in AML and MDS: The new (old) kid on the block. https://app.cochat.ai/papers/10.1016/j.blre.2023.101055
The paper
Marks, J. A., Wang, X., Fenu, E. M., Bagg, A., & Lai, C. (2023). TP53 in AML and MDS: The new (old) kid on the block. Blood Reviews. https://doi.org/10.1016/j.blre.2023.101055

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.